en · de · es · pt
melanotan-2-notes.peptides3626.com › Blog › Background And Chemical Profile — Field Notes

Background And Chemical Profile — Field Notes

By Editorial Desk · published 2026-03-18 · last reviewed 2026-04-01 · Blog

synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-04-01. Anything still debated is marked as such rather than presented as settled.

Background and Chemical Profile

The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Handling, Storage and Analytical Control

Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.

Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.

Melanotan-2 at a glance

PropertyValueNotes
Molecular classSynthetic cyclic heptapeptideAnalog of alpha-MSH with an internal lactam bridge
Molecular weightApproximately 1024 daltonsFree base value; salt forms differ
AppearanceWhite to off-white powderUsually supplied as a lyophilized solid
SolubilityFreely soluble in waterPoorly soluble in nonpolar solvents
Typical storage−20 °C, dry, protected from lightRepeated freeze-thaw cycles degrade peptides

Background and Mechanism of Melanotan-2

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Related pages on this site

Handling, Storage and Analytical Verification

Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.

The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.

Chemical Background and Receptor Activity

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.

Storage, Stability, and Analysis

Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.

Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.

Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.

Further detail

==== General indications ==== Doxycycline is a broad-spectrum antibiotic that is employed in the treatment of numerous bacterial infections. The drug is effective against bacteria such as Moraxella catarrhalis (a cause of respiratory tract infections), Brucella melitensis (a cause of brucellosis), Chlamydia pneumoniae (a cause of atypical pneumonia), and Mycoplasma pneumoniae (a cause of pneumonia). Additionally, doxycycline is used in the prevention and treatment of serious conditions like anthrax, leptospirosis, bubonic plague, and Lyme disease. However, some bacteria have developed resistance to doxycycline, including Haemophilus species, Mycoplasma hominis, and Pseudomonas aeruginosa. Specifically, doxycycline is indicated for treatment of the following diseases:

=== Medications === Prolactin secretion in the pituitary lactotroph cells is normally suppressed by the brain chemical dopamine, which binds to dopamine receptors. Drugs that block the effects of dopamine at the pituitary or deplete dopamine stores in the brain may cause the pituitary to secrete excess prolactin without an inhibitory effect. These drugs include the typical antipsychotics: phenothiazines such as chlorpromazine, and butyrophenones such as haloperidol; atypical antipsychotics such as risperidone and paliperidone; gastroprokinetic drugs used to treat gastro-esophageal reflux and medication-induced nausea (such as that from chemotherapy): metoclopramide and domperidone; less often, alpha-methyldopa and reserpine, used to control hypertension; and TRH. Aripiprazole, while an atypical antipsychotic, lowers prolactin levels as it is contains both agonistic and antagonistic dopamine-receptor activity. It is well known that estrogen stimulates prolactin secretion by upregulating the formation of lactotrophs. However, there is mixed evidence on whether estrogen-containing oral contraceptives significantly increase prolactin levels. Gender-affirming therapy for transgender women that includes estrogen and antiandrogens has been shown to increase prolactin levels, but it is unclear whether the cause is due to the estrogen or antiandrogen therapy. The melatonin receptor agonist ramelteon also increases the risk of hyperprolactinemia, however, the mechanism is unclear.

In 1809 the Tyroleans rose up against Bavarian authority and succeeded three times in defeating Bavarian and French troops trying to retake the country. Austria lost the War of the Fifth Coalition against France, and got harsh terms in the Treaty of Schönbrunn in 1809. Glorified as Tyrol's national hero, Andreas Hofer, the leader of the uprising, was executed in 1810 in Mantua. His forces had lost a fourth and final battle against the French and Bavarian forces. In 1810 Bavaria was forced by France to cede southern Tyrol (the Etschkreis plus Bozen) to the Kingdom of Italy, most of which became the Department of Alto Adige, and the eastern part of the Eisackkreis (roughly modern East Tyrol) to the French Empire's Illyrian Provinces. The remainder of the Eisackkreis was transferred to the Innkreis (along with Werdenfels and the newly-acquired Zillertal), while parts of the Innkreis were transferred to other Kreise: the eastern part around St. Johann and Kitzbühel to the Salzachkreis; the Lechtal in the north-west to the Illerkreis. Tyrol remained divided between Bavaria and Napoleonic Italy for another four years.

== Disease relevance == Due to its involvement in a great number of signaling pathways, GSK-3 has been associated with a host of high-profile diseases. GSK-3 inhibitors are currently being tested for therapeutic effects in Alzheimer's disease, type 2 diabetes mellitus (T2DM), some forms of cancer, and bipolar disorder. There is evidence that lithium, which is used as a treatment for bipolar disorder, acts as a mood stabilizer by selectively inhibiting GSK-3. The mechanism through which GSK-3 inhibition may stabilize mood is not known, though it is suspected that the inhibition of GSK-3's ability to promote inflammation contributes to the therapeutic effect. Inhibition of GSK-3 also destabilises Rev-ErbA alpha transcriptional repressor, which has a significant role in the circadian clock. Elements of the circadian clock may be connected with predisposition to bipolar mood disorder. GSK-3 activity has been associated with both pathological features of Alzheimer's disease, namely the buildup of amyloid-β (Aβ) deposits and the formation of neurofibrillary tangles. GSK-3 is thought to directly promote Aβ production and to be tied to the process of the hyperphosphorylation of tau proteins, which leads to the tangles. Due to these roles of GSK-3 in promoting Alzheimer's disease, GSK-3 inhibitors may have positive therapeutic effects on Alzheimer's patients and are currently in the early stages of testing. In a similar fashion, targeted inhibition of GSK-3 may have therapeutic effects on certain kinds of cancer.

Sources: en.wikipedia.org

Supporting material

Mahathir also strengthened political and economic cooperation with China, whilst maintaining diplomatic ambivalence on security issues to avoid escalating territorial disputes in the South China Sea. He openly criticised China's involvement in Malaysia's communist insurgency, but downplayed any military threat from China after the Cold War ended. In 1985, Mahathir visited China for the first time as prime minister, where he met Chinese leader Deng Xiaoping, establishing a new level of trust that laid the foundation for Malaysia-China relations and set the stage for decades of economic and diplomatic growth. Later, he visited China again in 1993, 1994, 1996, 1999, and twice in 2001. In the early 1990s, Mahathir played a key role in engaging China with ASEAN despite South China Sea disputes, particularly in the post-Tiananmen and post-Cold War contexts, paving the way for then Chinese Foreign Minister Qian Qichen to attend the ASEAN meeting's opening ceremony in July 1991 as a guest of the Malaysian government, and eventually leading to China's upgrade to ASEAN's dialogue partner in 1996. Amidst the Asian financial crisis, Mahathir also led several large delegations to China and Russia to seek regional economic cooperation. Besides that, Mahathir also had significant interactions with Taiwan, especially during the 1980s and 1990s, when economic ties between the two sides were at their strongest despite the lack of formal diplomatic relations.

In addition to pure indica, sativa, and ruderalis varieties, hybrid varieties with varying ratios of these three types are common, such as the White Widow hybrid which has about 60% indica and 40% sativa ancestry. These hybrid varieties exhibit traits from both parental types. There are also commercial crossbred hybrids which contain a mix of both ruderalis, indica or sativa genes, and are usually autoflowering varieties. "Lowryder" was an early auto-flowering hybrid that retained the flowering behavior of ruderalis plants, while also producing appreciable amounts of THC and CBD. Autoflowering cannabis varieties have the advantage of being discreet due to their small stature. They also require shorter growing periods, as well as having the additional advantage that they do not rely on a change in the photoperiod to determine when to flower. Breeding requires pollinating a female cannabis plant with male pollen. Although this occurs spontaneously and ubiquitously in nature, the intentional creation of new varieties typically involves selective breeding in a controlled environment.

fluorescence in situ hybridization (FISH) A type of in situ hybridization assay where the oligonucleotide probes are labelled with a chemical compound that is naturally fluorescent when exposed to light at particular wavelengths, making it possible to detect the in situ locations of complementary sequences with fluorescence microscopy. FISH is commonly used to visualize the physical locations of specific genes on chromosomes.

=== Other improvements === It is reported that in addition to the protein sequence, secondary structure formation depends on other factors. For example, it is reported that secondary structure tendencies depend also on local environment, solvent accessibility of residues, protein structural class, and even the organism from which the proteins are obtained. Based on such observations, some studies have shown that secondary structure prediction can be improved by addition of information about protein structural class, residue accessible surface area and also contact number information.

This mixture of cells is then diluted and clones are grown from single parent cells on microtitre wells. The antibodies secreted by the different clones are then assayed for their ability to bind to the antigen (with a test such as ELISA or antigen microarray assay) or immuno-dot blot. The most productive and stable clone is then selected for future use. The hybridomas can be grown indefinitely in a suitable cell culture medium. They can also be injected into mice (in the peritoneal cavity, surrounding the gut). There, they produce tumors secreting an antibody-rich fluid called ascites fluid. The medium must be enriched during in vitro selection to further favour hybridoma growth. This can be achieved by the use of a layer of feeder fibrocyte cells or supplement medium such as briclone. Culture-media conditioned by macrophages can be used. Production in cell culture is usually preferred as the ascites technique is painful to the animal. Where alternate techniques exist, ascites is considered unethical.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

How does it differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.

Is it the same as bremelanotide?

No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.

How is peptide purity usually reported?

Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.

Network